vs
Side-by-side financial comparison of DOMO, INC. (DOMO) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $79.4M, roughly 1.3× DOMO, INC.). DOMO, INC. runs the higher net margin — -13.1% vs -29.4%, a 16.3% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -0.5%). DOMO, INC. produced more free cash flow last quarter ($1.1M vs $-34.8M).
Domo, Inc. is an American cloud software company based in American Fork, Utah, United States. It specializes in artificial intelligence, business intelligence, and data visualization and is designed to provide real-time access to business data for decision makers across the company with minimal IT involvement. It is a Software-as-a-Service (SaaS) venture.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
DOMO vs TWST — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $79.4M | $103.7M |
| Net Profit | $-10.4M | $-30.5M |
| Gross Margin | 74.2% | 52.0% |
| Operating Margin | -8.7% | -31.7% |
| Net Margin | -13.1% | -29.4% |
| Revenue YoY | -0.5% | 16.9% |
| Net Profit YoY | 44.6% | 3.4% |
| EPS (diluted) | $-0.25 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $79.4M | $103.7M | ||
| Q3 25 | $79.7M | — | ||
| Q2 25 | $80.1M | — | ||
| Q1 25 | $78.8M | — | ||
| Q4 24 | $79.8M | — | ||
| Q3 24 | $78.4M | — | ||
| Q2 24 | $80.1M | — | ||
| Q1 24 | $80.2M | — |
| Q4 25 | $-10.4M | $-30.5M | ||
| Q3 25 | $-22.9M | — | ||
| Q2 25 | $-18.1M | — | ||
| Q1 25 | $-17.7M | — | ||
| Q4 24 | $-18.8M | — | ||
| Q3 24 | $-19.5M | — | ||
| Q2 24 | $-26.0M | — | ||
| Q1 24 | $-18.7M | — |
| Q4 25 | 74.2% | 52.0% | ||
| Q3 25 | 74.8% | — | ||
| Q2 25 | 74.2% | — | ||
| Q1 25 | 74.4% | — | ||
| Q4 24 | 75.0% | — | ||
| Q3 24 | 74.3% | — | ||
| Q2 24 | 74.1% | — | ||
| Q1 24 | 76.3% | — |
| Q4 25 | -8.7% | -31.7% | ||
| Q3 25 | -9.1% | — | ||
| Q2 25 | -17.9% | — | ||
| Q1 25 | -15.6% | — | ||
| Q4 24 | -13.9% | — | ||
| Q3 24 | -18.5% | — | ||
| Q2 24 | -26.8% | — | ||
| Q1 24 | -16.6% | — |
| Q4 25 | -13.1% | -29.4% | ||
| Q3 25 | -28.8% | — | ||
| Q2 25 | -22.5% | — | ||
| Q1 25 | -22.4% | — | ||
| Q4 24 | -23.5% | — | ||
| Q3 24 | -24.9% | — | ||
| Q2 24 | -32.5% | — | ||
| Q1 24 | -23.3% | — |
| Q4 25 | $-0.25 | $-0.50 | ||
| Q3 25 | $-0.56 | — | ||
| Q2 25 | $-0.45 | — | ||
| Q1 25 | $-0.45 | — | ||
| Q4 24 | $-0.48 | — | ||
| Q3 24 | $-0.51 | — | ||
| Q2 24 | $-0.69 | — | ||
| Q1 24 | $-0.51 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $197.9M |
| Total DebtLower is stronger | $124.2M | — |
| Stockholders' EquityBook value | $-191.9M | $456.1M |
| Total Assets | $201.6M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $197.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | $47.2M | — | ||
| Q1 25 | $45.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $61.2M | — | ||
| Q1 24 | $60.9M | — |
| Q4 25 | $124.2M | — | ||
| Q3 25 | $121.9M | — | ||
| Q2 25 | $119.7M | — | ||
| Q1 25 | $117.7M | — | ||
| Q4 24 | $115.6M | — | ||
| Q3 24 | $115.2M | — | ||
| Q2 24 | $114.1M | — | ||
| Q1 24 | $113.5M | — |
| Q4 25 | $-191.9M | $456.1M | ||
| Q3 25 | $-191.5M | — | ||
| Q2 25 | $-178.7M | — | ||
| Q1 25 | $-177.2M | — | ||
| Q4 24 | $-171.2M | — | ||
| Q3 24 | $-166.4M | — | ||
| Q2 24 | $-163.5M | — | ||
| Q1 24 | $-153.5M | — |
| Q4 25 | $201.6M | $638.1M | ||
| Q3 25 | $195.7M | — | ||
| Q2 25 | $189.7M | — | ||
| Q1 25 | $214.3M | — | ||
| Q4 24 | $190.2M | — | ||
| Q3 24 | $197.8M | — | ||
| Q2 24 | $204.4M | — | ||
| Q1 24 | $225.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.4M | $-24.8M |
| Free Cash FlowOCF − Capex | $1.1M | $-34.8M |
| FCF MarginFCF / Revenue | 1.4% | -33.5% |
| Capex IntensityCapex / Revenue | 2.9% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $9.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.4M | $-24.8M | ||
| Q3 25 | $3.4M | — | ||
| Q2 25 | $4.0M | — | ||
| Q1 25 | $8.9M | — | ||
| Q4 24 | $-13.7M | — | ||
| Q3 24 | $-6.2M | — | ||
| Q2 24 | $1.9M | — | ||
| Q1 24 | $5.4M | — |
| Q4 25 | $1.1M | $-34.8M | ||
| Q3 25 | $1.0M | — | ||
| Q2 25 | $1.0M | — | ||
| Q1 25 | $6.7M | — | ||
| Q4 24 | $-16.2M | — | ||
| Q3 24 | $-8.4M | — | ||
| Q2 24 | $-625.0K | — | ||
| Q1 24 | $2.9M | — |
| Q4 25 | 1.4% | -33.5% | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 8.5% | — | ||
| Q4 24 | -20.3% | — | ||
| Q3 24 | -10.7% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | 3.6% | — |
| Q4 25 | 2.9% | 9.6% | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 3.7% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | 3.2% | — | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMO
| Subscription | $71.9M | 91% |
| Professional Servicesand Other | $7.5M | 9% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
